Antimicrobial Pathogens : Alternative Approaches
Infections of antibiotic-resistant pathogens cause an ever-increasing threat to mankind. The investigation of novel approaches to deal with the antimicrobial resistance crisis should be part of global response to present drawback if an untimely reversion to the pre-penicillin era of medicine is to be avoided. One such promising avenue of analysis involves so-called antibiotic resistance breakers (ARBs), capable of re-sensitising resistant bacteria to antibiotics. Multidrug-resistant bacteria are getting more common and due to their multiplicity of mechanisms, they are frequently resistant to several if not all of the current antibiotics. This intimidating spectre has been the target of several research efforts into conventional antibiotics and alternative approaches. Bacteria have developed the capability to supply structured communities (or cluster of cells) via adherence to surface to form biofilms that facilitate or prolong their survival beneath extreme environmental condition.
Related Conference of Antimicrobial Pathogens : Alternative Approaches
9th International Conference on Vaccines, Immunology and Clinical Trials
Antimicrobial Pathogens : Alternative Approaches Conference Speakers
Recommended Sessions
- Antibiotics, Antimicrobial & Chemotherapy
- Antimicrobial Pathogens : Alternative Approaches
- Antimicrobials
- Antimicrobiology in Epidemiology
- COVID 19 in Antimicrobial and Antibacterial Agents
- Global Spread of Viruses
- Immunity , Infection Diseases and Agents
- Microbial Immunology
- Microbial Physiology and Metabolism
- Microorganisms in Recent Drug Discovery
- Pharmaceutical microbiology
- Pharmalogical Consideration of Infectious Disease and Agents
- Vaccine and Vaccination
- Vaccines and Therapeutics
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2025 (Canada)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Germany)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Antinatal vaccinations - Vaccines Congress-2025 (Canada)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Germany)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials - VACCINES WORLD 2025 (Germany)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Germany)
- Conjugated and combination vaccinations - Vaccines Congress-2025 (Canada)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Germany)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Creation and development of vaccines - Vaccines Congress-2025 (Canada)
- DNA Vaccines - Euro Vaccines 2025 (France)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2025 (Canada)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Germany)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Germany)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Germany)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2025 (Canada)
- HIV Vaccines - VACCINES WORLD 2025 (Germany)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immune Profiling - VACCINES WORLD 2025 (Germany)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Germany)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Germany)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- rDNA technology in vaccine development - Vaccines Congress-2025 (Canada)
- Recent advances in vaccine development - Vaccines Congress-2025 (Canada)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2025 (Canada)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Germany)
- Toxoid vaccination - Vaccines Congress-2025 (Canada)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Germany)
- Vaccine and Vaccination - Vaccines Congress-2025 (Canada)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2025 (Canada)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2025 (Canada)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2025 (Canada)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Germany)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Research and Clinical trials - Vaccines Congress-2025 (Canada)
- Vaccine Research and Development - VACCINES WORLD 2025 (Germany)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Germany)
- Vaccines against non-traditional illnesses - Vaccines Congress-2025 (Canada)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- VACCINES FOR CANCER - Vaccines Congress-2025 (Canada)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Veterinary Vaccine - VACCINES WORLD 2025 (Germany)
- Veterinary Vaccines - Euro Vaccines 2025 (France)
- Zika Virus vaccines - Vaccines Congress-2025 (Canada)